Company profile
CANDEL THERAPEUTICS, INC.
NASDAQ:CADLBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| AGLATIMAGENE BESADENOVEC | phase3 | — | 11 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (13)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07332000 | phase2 | recruiting | 2025-10-30 | 2027-02-01 | Candel Therapeutics, Inc. | A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec |
| NCT00634231 | phase1 | completed | 2010-10-01 | 2015-12-01 | Candel Therapeutics, Inc. | A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors |
| NCT00638612 | phase1 | completed | 2008-08-01 | 2013-05-01 | Candel Therapeutics, Inc. | AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01) |
| NCT07660094 | phase3 | recruiting | 2026-06-15 | 2031-10-22 | Candel Therapeutics, Inc. | Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA) |
| NCT04495153 | phase2 | active_not_recruiting | 2020-10-13 | 2024-12-31 | Candel Therapeutics, Inc. | CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC |
FDA applications (0)
No records yet.